Net Income (Loss) Attributable to Parent of Enliven Therapeutics, Inc. from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Enliven Therapeutics, Inc. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Mar 2019 to 31 Dec 2025.
  • Enliven Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Dec 2025 was $29,667,000, a 28% decline year-over-year.
  • Enliven Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Dec 2025 was $103,694,000, a 16% decline year-over-year.
  • Enliven Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2025 was $103,694,000, a 16% decline from 2024.
  • Enliven Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $89,024,000, a 24% decline from 2023.
  • Enliven Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $71,584,000, a 90% decline from 2022.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Enliven Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $103,694,000 $29,667,000 -$6,487,000 -28% 01 Oct 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
Q3 2025 $97,207,000 $20,148,000 +$3,008,000 +13% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $100,215,000 $25,335,000 -$5,385,000 -27% 01 Apr 2025 30 Jun 2025 10-Q 12 Nov 2025 2025 Q3
Q1 2025 $94,830,000 $28,544,000 -$5,806,000 -26% 01 Jan 2025 31 Mar 2025 10-Q 12 Nov 2025 2025 Q3
Q4 2024 $89,024,000 $23,180,000 -$3,810,000 -20% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
Q3 2024 $85,214,000 $23,156,000 -$2,387,000 -11% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $82,827,000 $19,950,000 -$3,229,000 -19% 01 Apr 2024 30 Jun 2024 10-Q 12 Nov 2025 2025 Q3
Q1 2024 $79,598,000 $22,738,000 -$8,014,000 -54% 01 Jan 2024 31 Mar 2024 10-Q 12 Nov 2025 2025 Q3
Q4 2023 $71,584,000 $19,370,000 -$9,820,000 -103% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $61,764,000 $20,769,000 -$10,215,000 -97% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $51,549,000 $16,721,000 -$7,832,000 -88% 01 Apr 2023 30 Jun 2023 10-Q 13 Nov 2024 2024 Q3
Q1 2023 $43,717,000 $14,724,000 -$6,055,000 -70% 01 Jan 2023 31 Mar 2023 10-Q 13 Nov 2024 2024 Q3
Q4 2022 $37,662,000 $9,550,000 -$21,875,000 -177% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $15,787,000 $10,554,000 +$3,093,000 +23% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $18,880,000 $8,889,000 +$4,272,000 +32% 01 Apr 2022 30 Jun 2022 10-Q 09 Nov 2023 2023 Q3
Q1 2022 $23,152,000 $8,669,000 +$1,588,000 +15% 01 Jan 2022 31 Mar 2022 10-Q 09 Nov 2023 2023 Q3
Q4 2021 $24,740,000 $12,325,000 +$23,843,000 01 Oct 2021 31 Dec 2021 8-K 23 Jun 2023
Q3 2021 $48,583,000 $13,647,000 -$1,224,000 -9.9% 01 Jul 2021 30 Sep 2021 10-Q 25 Oct 2022 2022 Q3
Q2 2021 $47,359,000 $13,161,000 -$2,957,000 -29% 01 Apr 2021 30 Jun 2021 10-Q 25 Oct 2022 2022 Q3
Q1 2021 $44,402,000 $10,257,000 -$3,042,000 -42% 01 Jan 2021 31 Mar 2021 10-Q 25 Oct 2022 2022 Q3
Q4 2020 $41,360,000 $11,518,000 -$4,268,000 -59% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q3 2020 $37,092,000 $12,423,000 -$5,801,000 -88% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $31,291,000 $10,204,000 -$4,807,000 -89% 01 Apr 2020 30 Jun 2020 10-Q 09 Nov 2021 2021 Q3
Q1 2020 $26,484,000 $7,215,000 -$3,021,000 -72% 01 Jan 2020 31 Mar 2020 10-Q 09 Nov 2021 2021 Q3
Q4 2019 $23,463,000 $7,250,000 01 Oct 2019 31 Dec 2019 10-K 05 Mar 2021 2020 FY
Q3 2019 $6,622,000 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $5,397,000 01 Apr 2019 30 Jun 2019 10-Q 05 Nov 2020 2020 Q3
Q1 2019 $4,194,000 01 Jan 2019 31 Mar 2019 10-Q 05 Nov 2020 2020 Q3

Enliven Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $103,694,000 -$14,670,000 -16% 01 Jan 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
2024 $89,024,000 -$17,440,000 -24% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
2023 $71,584,000 -$33,922,000 -90% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $37,662,000 -$12,922,000 -52% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $24,740,000 +$16,620,000 +40% 01 Jan 2021 31 Dec 2021 8-K 23 Jun 2023
2020 $41,360,000 -$17,897,000 -76% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
2019 $23,463,000 01 Jan 2019 31 Dec 2019 10-K 05 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.